KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $48.5 million.

  • Rigel Pharmaceuticals' Cash & Equivalents fell 6.11% to $48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year decrease of 6.11%. This contributed to the annual value of $56.7 million for FY2024, which is 73.08% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Cash & Equivalents stood at $48.5 million, which was down 9.12% from $53.4 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Cash & Equivalents' 5-year high stood at $84.8 million during Q2 2021, with a 5-year trough of $18.9 million in Q4 2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $45.7 million (2025), whereas its average is $44.1 million.
  • In the last 5 years, Rigel Pharmaceuticals' Cash & Equivalents soared by 132.59% in 2021 and then crashed by 67.93% in 2022.
  • Rigel Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $18.9 million in 2021, then rose by 29.48% to $24.5 million in 2022, then surged by 34.04% to $32.8 million in 2023, then surged by 73.08% to $56.7 million in 2024, then fell by 6.11% to $48.5 million in 2025.
  • Its Cash & Equivalents was $48.5 million in Q3 2025, compared to $53.4 million in Q2 2025 and $45.7 million in Q1 2025.